Get the Stockscreener App
20.77
1.56%
-0.33
After Hours:
20.77
Arrivent Biopharma Inc stock is traded at $20.77, with a volume of 286.03K.
It is down -1.56% in the last 24 hours and down -10.16% over the past month.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
See More
Previous Close:
$21.10
Open:
$21.2
24h Volume:
286.03K
Relative Volume:
1.09
Market Cap:
$838.21M
Revenue:
-
Net Income/Loss:
$-81.05M
P/E Ratio:
-7.9178
EPS:
-2.6232
Net Cash Flow:
$-68.97M
1W Performance:
-8.94%
1M Performance:
-10.16%
6M Performance:
-24.53%
1Y Performance:
+13.68%
1-Day Range:
$20.01
$21.20
1-Week Range:
$20.00
$23.26
52-Week Range:
$15.47
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Name
Arrivent Biopharma Inc
Sector
Industry
Phone
240-780-6356
Address
18 CAMPUS BLVD., NEWTOWN SQUARE
Compare AVBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
20.77 | 838.21M | 0 | -81.05M | -68.97M | -2.6232 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-25 | Initiated | B. Riley Securities | Buy |
| Mar-10-25 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Oppenheimer | Outperform |
| Apr-30-24 | Initiated | H.C. Wainwright | Buy |
| Feb-20-24 | Initiated | Citigroup | Buy |
| Feb-20-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | Jefferies | Buy |
View All
Arrivent Biopharma Inc Stock (AVBP) Latest News
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases New Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Acquired by California State Teachers Retirement System - Defense World
Where are the Opportunities in (AVBP) - news.stocktradersdaily.com
Bank of America Corp DE Raises Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Millennium Management LLC Reduces Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Comparing Immutep (NASDAQ:IMMP) and ArriVent BioPharma (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Rating of “Buy” by Analysts - Defense World
Cencora Welcomes Lori J. Ryerkerk to Board of Directors - MyChesCo
BNP Paribas Financial Markets Decreases Stock Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 1,327 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Promising Outlook for ArriVent BioPharma: Buy Rating Justified by Upcoming EGFR PACC Mutant NSCLC Program Updates - TipRanks
Deutsche Bank AG Boosts Stock Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.5% – Here’s What Happened - Defense World
Wall Street Zen Upgrades Atea Pharmaceuticals (NASDAQ:AVIR) to “Hold” - Defense World
Wall Street Zen Downgrades ArriVent BioPharma (NASDAQ:AVBP) to Strong Sell - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Coverage Initiated at Jones Trading - Defense World
JonesResearch Begins Coverage on ArriVent Biopharma (AVBP) with - GuruFocus
ArriVent BioPharma (AVBP) Coverage Initiated with 'Buy' Rating | - GuruFocus
JonesResearch Begins Coverage on ArriVent Biopharma (AVBP) with Optimistic Outlook | AVBP Stock News - GuruFocus
Northern Trust Corp Purchases 10,498 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Northern Trust Corp Boosts Stock Position in AxoGen, Inc. (NASDAQ:AXGN) - Defense World
ArriVent BioPharma Reports Q1 2025 Financial Results and Highlights Key Achievements - MSN
Arbutus Biopharma Reports Q1 2025 Results, Clinical Developments, and Legal Progress - MyChesCo
When the Price of (AVBP) Talks, People Listen - news.stocktradersdaily.com
Q2 EPS Estimates for ArriVent BioPharma Cut by HC Wainwright - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $40.00 - Defense World
Price T Rowe Associates Inc. MD Has $293,000 Stock Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
B. Riley Lifts Earnings Estimates for ArriVent BioPharma - Defense World
Synnovation Therapeutics Welcomes Rafael G. Amado, M.D., to Board of Directors - MyChesCo
ArriVent BioPharma (AVBP) Receives Price Target Increase by HC W - GuruFocus
Is ArriVent BioPharma (NASDAQ:AVBP) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
ArriVent Biopharma (AVBP) Price Target Increased by Analyst | AV - GuruFocus
ArriVent Biopharma (AVBP) Price Target Increased by Analyst | AVBP Stock News - GuruFocus
Voya Investment Management LLC Acquires Shares of 8,373 ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Tower Research Capital LLC TRC Has $43,000 Stock Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
ArriVent BioPharma, Inc. SEC 10-Q Report - TradingView
ArriVent Biopharma (AVBP) Projects Financial Stability Through 2 - GuruFocus
ArriVent Biopharma (AVBP) Projects Financial Stability Through 2026 | AVBP Stock News - GuruFocus
ArriVent (AVBP) Advances Oncology Pipeline with Key Milestones Ahead | AVBP Stock News - GuruFocus
ArriVent BioPharma Reports First Quarter 2025 Financial Results - The Manila Times
ArriVent BioPharma (AVBP) Expected to Announce Earnings on Wednesday - Defense World
How to Take Advantage of moves in (AVBP) - news.stocktradersdaily.com
Arrivent Biopharma Inc expected to post a loss of 66 cents a shareEarnings Preview - TradingView
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Acquired by Wells Fargo & Company MN - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Down – Here’s Why - Defense World
Barclays PLC Grows Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Invesco Ltd. Takes Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Acquired by JPMorgan Chase & Co. - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Update - Defense World
Legal & General Group Plc Purchases 10,783 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Arrivent Biopharma Inc Stock (AVBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):